[Form 4] HELIOS TECHNOLOGIES, INC. Insider Trading Activity
Ian K. Walsh, a director of Helios Technologies, Inc. (HLIO), was granted 697 restricted stock units (RSUs) on 09/18/2025. Each RSU converts to one share of common stock upon vesting. The RSUs were reported as acquired at a $0 purchase price and are exercisable/vest on 09/18/2026; following the transaction Walsh beneficially owns 697 shares directly. The Form 4 was signed by an attorney-in-fact on 09/19/2025. The filing discloses a routine equity grant to an insider and provides no additional compensation terms or cash consideration beyond the RSU grant.
- Alignment of interests: Director received equity compensation, which aligns his interests with shareholders through future ownership upon vesting
- Clear disclosure: Filing provides specific grant size (697 RSUs), vesting date (09/18/2026), and direct beneficial ownership after the grant (697 shares)
- None.
Insights
TL;DR: Director received a standard equity grant (697 RSUs) vesting in one year; routine insider compensation disclosure.
The Form 4 shows a noncash grant of 697 restricted stock units to a director, with vesting/exercise on 09/18/2026 and a $0 reported acquisition price, indicating a typical equity-based retention or alignment award rather than a market purchase. As reported, ownership is direct and limited to the 697 underlying shares. There is no indication in the filing of accelerated vesting, performance conditions, or supplemental cash payments. For governance review, this appears to be a customary director grant requiring routine disclosure under Section 16.
TL;DR: The transaction is administratively material for disclosure but unlikely to be materially impactful on HLIO's capital structure.
The reported issuance of 697 RSUs increases the director's potential share count by 697 shares upon vesting. The grant price is listed as $0, consistent with RSU awards that convert to common stock without a purchase price. The filing contains no information on aggregate outstanding shares, dilutive impact, or any sale following vesting, so market-impact conclusions cannot be drawn from this Form 4 alone.